Syndax Pharmaceuticals Inc (NASDAQ: SNDX) is 8.77% higher on its value in year-to-date trading and has touched a low of $12.06 and a high of $25.16 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SNDX stock was last observed hovering at around $15.48 in the last trading session, with the day’s loss setting it -1.1%.
Currently trading at $14.38, the stock is -5.52% and 1.20% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.01 million and changing -7.11% at the moment leaves the stock -20.76% off its SMA200. SNDX registered -38.65% loss for a year compared to 6-month loss of -28.85%.
The stock witnessed a 1.48% gain in the last 1 month and extending the period to 3 months gives it a -12.90%, and is -5.64% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.11% over the week and 5.69% over the month.
Syndax Pharmaceuticals Inc (SNDX) has around 270 employees, a market worth around $1.24B and $23.68M in sales. Profit margin for the company is -1346.11%. Distance from 52-week low is 19.24% and -42.85% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.31%).
with sales reaching $11.36M over the same period.The EPS is expected to shrink by -3.62% this year, but quarterly earnings will post 209.66% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Syndax Pharmaceuticals Inc (SNDX) Top Institutional Holders
The shares outstanding are 85.69M, and float is at 83.50M with Short Float at 25.81%.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.91 million shares valued at $162.33 million. The investor’s holdings represent 9.2788% of the SNDX Shares outstanding. As of 2024-06-30, the second largest holder is WELLINGTON MANAGEMENT GROUP LLP with 7.34 million shares valued at $$150.67 million to account for 8.6125 of the shares outstanding. The other top investors are KYNAM CAPITAL MANAGEMENT, LP which holds 5.72 million shares representing 6.7101% and valued at over $117.47 million, while VANGUARD GROUP INC holds 5.6295 of the shares totaling 4.8 million with a market value of $98.48 million.
Syndax Pharmaceuticals Inc (SNDX) Insider Activity
A total of 0 insider transactions have happened at Syndax Pharmaceuticals Inc (SNDX) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Syndax Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 10 ’25 that Goldan Keith A. (Chief Financial Officer) sold a total of 3,777 shares of the company’s common stock. The trade occurred on Feb 10 ’25 and was made at $15.50 per share for $58559.0. Following the transaction, the insider now directly holds 90746.0 shares of the SNDX stock.
Still, SEC filings show that on Feb 10 ’25, Metzger Michael A (Chief Executive Officer) disposed off 13,288 shares at an average price of $15.50 for $0.21 million. The insider now directly holds 300,121 shares of Syndax Pharmaceuticals Inc (SNDX).
Syndax Pharmaceuticals Inc (SNDX): Who are the competitors?
The company’s main competitors (and peers) include Ono Pharmaceutical Co. Ltd. ADR (OPHLY) that is trading -33.62% down over the past 12 months. Omeros Corp. (OMER) that is 89.55% higher over the same period.
